J&J's 1B acquisition of Firefly Bio adds the Firelink DAC platform for KRAS-driven tumors, introducing degrader antibody conjugates as a novel modality beyond ADCs.

GSK's 10.6 billion acquisition of Nuvalent adds zidesamtinib and neladalkib, next-generation ROS1 and ALK inhibitors for NSCLC. For API and intermediate suppliers, the deal signals growing demand for complex small-molecule kinase inhibitor manufacturing.

Jazz Pharmaceuticals Zepzelca failed Phase III Lagoon trial in second-line SCLC, creating uncertainty for lurbinectedin API supply chain and highlighting regulatory risk in oncology manufacturing.

FDA approved Merck's Keytruda and Keytruda Qlex with Pfizer's Welireg for prostate cancer, creating new demand for ADC and bispecific antibody manufacturing.